2. Search Result
Search Result
Results for "

Non-Hodgkin's Lymphoma

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

4

Inhibitory Antibodies

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-P99289
    Epratuzumab

    Antibody hLL 2; AMG-412

    		 CD22 Inflammation/Immunology Cancer
    Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
    Epratuzumab
  • HY-106634
    Mitoguazone
    5 Publications Verification

    Methylglyoxal-bis(guanylhydrazone); MGBG; Methyl-GAG

    		 HIV Apoptosis Infection Cancer
    Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment .
    Mitoguazone
  • HY-P9959
    Inotuzumab ozogamicin

    CMC-544; PF-5208773; WAY-207294

    		 Antibody-Drug Conjugates (ADCs) CD22 Cancer
    Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .
    Inotuzumab ozogamicin
  • HY-156640
    Rocbrutinib

    LP-168

    		 EGFR Cancer
    Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma .
    Rocbrutinib
  • HY-12908
    Bcl-xL antagonist 2

    		Bcl-2 Family Apoptosis Cancer
    Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .
    Bcl-xL antagonist 2
  • HY-P991085
    HX009

    		PD-1/PD-L1 Cancer
    HX009 is a bispecific antibody targeting PD1 and CD47, but with weakened CD47 binding. HX009 blocks the functional of PD1/CD47. HX009 can be used for the study of non-Hodgkin’s lymphoma (NHL) .
    HX009
  • HY-P991647
    ALX-0651

    		CXCR Cancer
    ALX-0651 is a biparatopic humanized monoclonal antibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
    ALX-0651
  • HY-106634R
    Mitoguazone (Standard)

    Methylglyoxal-bis(guanylhydrazone) (Standard); MGBG (Standard); Methyl-GAG (Standard)

    		 Reference Standards HIV Apoptosis Infection Cancer
    Mitoguazone (Standard) is the analytical standard of Mitoguazone. This product is intended for research and analytical applications. Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment .
    Mitoguazone (Standard)
  • HY-149221
    Apoptosis inducer 11

    		Apoptosis Cancer
    Apoptosis inducer 11 (compound 3u) induces apoptosis through the mitochondrial pathway. Apoptosis inducer 11 induces a block in G2/M, a strong decrease in S phase in non-Hodgkin lymphoma cell lines .
    Apoptosis inducer 11
  • HY-101798
    MDVN1003

    		PI3K Cancer
    MDVN1003 is a Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ) dual inhibitor which prevents the activation of B cells and inhibits the phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2). MDVN1003 can be used for non-Hodgkin’s lymphoma (NHL) research .
    MDVN1003
  • HY-P992417
    MT-3724

    		CD20 Apoptosis Cancer
    MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma .
    MT-3724

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: